
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is poised for success with their innovative T cell programming technologies and a strong product pipeline for addressing a range of diseases. The company's positive financial results and growth into new markets, as well as promising data from clinical trials, make it a compelling investment opportunity for those with a long-term outlook. However, risks must be considered, such as potential competition and the challenges of successfully bringing new therapies to market.
Bears say
Autolus Therapeutics is facing challenges in attracting investors due to competition in the market, potential side effects of their therapies, and high development costs. While Autolus Therapeutics has reported strong earnings and progress in launching their CAR-T therapy, Aucatzyl, for B-ALL, their slightly lower earnings in the first quarter and potential side effects of their therapies may raise concerns for investors. The company is expected to see growth in authorized treatment centers and additional expansion in the UK, but competition in the market and high development costs pose challenges for the company's future success. Additionally, the use of the 4-1BB co-stimulatory domain in their therapies may provide a unique safety and efficacy profile, but their ongoing efforts to increase manufacturing capacity and improve processes are crucial for their success in the highly competitive biopharmaceutical industry.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares